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Abstract
Background: The speed and sensitivity of real-time polymerase chain reaction (PCR) have made
it a popular method for the detection of microbiological agents in both research and clinical
specimens. For the detection and genotyping of herpes simplex virus (HSV) in clinical specimens,
real-time PCR has proven to be faster, more sensitive and safer than earlier methods which
included isolation of the virus in cell culture followed by immunofluorescence microscopy. While
PCR-based assays for HSV detection posses clear advantages over these earlier techniques, certain
aspects of the PCR method remain onerous. The process of extraction and purification of nucleic
acid from clinical specimens prior to PCR is particularly cumbersome. Nucleic acid extraction is
expensive, time-consuming and provides a step whereby specimens can become contaminated
prior to their analysis. Herein, we investigate the necessity of nucleic acid extraction from swab-
based clinical specimens for HSV detection by real-time PCR. We find that nucleic acid extraction
is unnecessary for specific and sensitive detection of HSV in clinical specimens using real-time PCR.
Methods:  Prospective (n = 36) and retrospective (n = 21) clinical specimens from various
anatomical sites were analyzed for the presence of herpes simplex virus 1 or 2 by real-time PCR
using the RealArt HSV 1/2 LC PCR Kit. Specimens were analyzed by PCR both before and following
automated nucleic acid extraction. PCR using extracted and unextracted specimens was also
compared to cell culture as a means of detecting HSV.
Results: Detection of HSV 1/2 DNA in clinical specimens by real-time PCR did not require that
the specimen be subjected to nucleic acid extraction/purification prior to analysis. Each specimen
that was detectable by real-time PCR when analyzed in the extracted form was also detectable
when analyzed in the unextracted form using the methods herein. The limit of detection of HSV-1
and HSV-2 particles when analyzed in the unextracted form was found to be approximately 17 and
32 virus particles respectively, compared to a sensitivity of 10 copies, for analysis of purified DNA.
Omission of the nucleic acid extraction step shortened both the assay time and cost.
Conclusion: Omission of the nucleic acid extraction step prior to real-time PCR for detection of
herpes simplex virus resulted in a more rapid and cost-effective assay, with little impact upon the
sensitivity of detection.
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Background
Reliable methods for detection and sub-typing of HSV
infections have included enzyme-linked immunosorbent
assay (ELISA), immunofluorescence microscopy (IFA)
and virus isolation by cell culture. While each of these
methods has been very useful in assisting clinical diagno-
sis, time and technological progress have revealed the lim-
itations of these assays. All three assays are laborious and
time consuming, with cell culture often requiring as long
as seven days before results are obtained. The sensitivities
of these techniques have also been questioned, particu-
larly in reference to more recent methodologies, such as
polymerase chain reaction (PCR). The advent of real-time
PCR for sensitive and rapid detection of nucleic acid
sequences has had a significant impact upon detection of
infectious disease agents. Many laboratories, including
our own, have adopted real-time PCR as the primary
method for detection of HSV due to the speed, sensitivity
and relative lack of complexity of the real-time PCR
method [1-4]. Typically, specimens analyzed by real-time
PCR must first be processed in such a way that nucleic acid
is extracted and purified from the clinical specimen. The
extracted nucleic acid is used as a reactant in PCR to deter-
mine if the DNA sequences of interest (i.e. an infectious
agent) are present. Extractions of DNA are deemed neces-
sary due to both assumption and empirical observation
that the efficiency of PCR chemistry can be negatively
affected by constituents of biological specimens. While it
is true that gross contamination of nucleic acid specimens
with biological and chemical factors can inhibit PCR,
there are few if any reliable trends which describe such
inhibition. Polymerase chain reactions require evaluation
on a case-by-case basis to determine their efficiency.
Herein, we show that HSV specimens (swabs diluted in a
widely-used, commercially available viral transport
buffer) are capable of being analyzed by PCR in the
absence of any purification or extraction of nucleic acid.
Performing PCR on crude specimens does not require any
sacrifice of specificity and requires only a minor sacrifice
of assay sensitivity.
Methods
Specimens (n = 36) considered for possible HSV infection
were collected from outpatients of the STD clinic during
October 2005. Specimens were taken by swabbing of
lesions, rashes or ulcers from various anatomical sites,
including genital (male and female), rectal (male) and
facial (male). Swabs were placed into 2 ml of either Cell-
matics or Universal Transport Kit buffer (Becton Dickin-
son, Sparks, MD). Specimens were refrigerated at 4°C
until analyzed, and subsequently frozen at -35°C. Retro-
spective specimens (n = 21) taken between June 2005 and
October 2005 and stored at -35°C were also chosen for
analysis. Retrospective specimens were chosen from males
(n = 13) and females (n = 8), from various anatomical
sites (genital, rectal, facial). Aliquots (1 ml) of all prospec-
tive and retrospective specimens were combined with
A549 cells (Viromed Laboratories, Minnetonka, MN) in
shell vials and placed at 37°C. Cultures were visualized
24, 48, 72 and 168 hours after initiation for determina-
tion of the presence or absence of cytopathic effect. If cyto-
pathic effect was noted within a cultured specimen, cells
from that culture were harvested and smeared onto glass
slides prior to being fixed and subjected to immunofluo-
rescent microscopy using the PathoDx Herpes Typing Kit
(Remel, Lenexa, KS) in order to confirm the detection of
HSV and to determine HSV type (1 or 2)
For detection of HSV by real-time PCR, samples (200 μl)
of each clinical specimen were combined with 200 μl of
MagNAPure LC Lysis Buffer and subjected to automated
nucleic acid extraction using a MagNAPure LC (Roche
Diagnostics, Indianapolis, IN) programmed for Total
"Nucleic Acid Extraction Kit I" with external lysis. Final
elution volume of each sample at the conclusion of
nucleic extraction was 50 μl. Specimens were either ana-
lyzed by PCR immediately following extraction, or were
stored at -35°C. PCR for the detection of HSV 1/2 DNA
was carried out using the RealArt HSV 1/2 LC PCR Kit
(Qiagen, Germantown, MD). Reactions were set-up and
performed according to manufacturer's instructions. In
cases of extracted specimens, 5 μl of extracted sample was
added to 15 μl of PCR Master Mix and 0.5 μl of internal
control DNA. For unextracted samples, 1 μl of clinical
specimen was combined with 4 μl of deionized water, 0.5
μl of internal control DNA and 15 μl of PCR Master Mix.
All reactions were performed in a LightCycler 2.0 (Roche,
Indianapolis, IN). Data analysis was carried-out using
LightCycler 4.0 software, with criteria for positive detec-
tion of HSV being designated as any specimen having a
crossing point (CP value) less than 30 (using the 640 nm/
back 530 nm channel for analysis). This CP value was cho-
sen as follows: Based on our laboratory results, 10 purified
HSV-2 DNA copies was found to be detectable 100% of
the time (4/4 attempts in one experiment), with the high-
est CP value being 26.77. Five copies was not detectable
(0/4 attempts in two experiments). Results were similar
for HSV-1, with 25.53 being the highest CP for detection
of 10 purified DNA copies. Hence, for purposes of this
work, we set the upper boundary for calling an HSV spec-
imen positive at approximately three crossing points
higher than 26.77 (to a CP of 30) to account for the pos-
sibility of delays in amplification caused by potential
impurities when unextracted clinical specimens are ana-
lyzed. Specimens with crossing points greater than 30
were considered negative for HSV. In accordance with the
Code of Federal Regulations Title 45 Part 46, this work is
exempt from human subjects review as this research
involved the study of diagnostic specimens in a mannerBMC Infectious Diseases 2006, 6:104 http://www.biomedcentral.com/1471-2334/6/104
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that patients cannot be identified either directly or
through identifiers linked to the specimens.
Results
Determining the feasibility of efficient detection of HSV 
DNA by real-time PCR on untreated clinical specimens
Having established real-time PCR within our laboratory as
the method of choice for detection of HSV in clinical spec-
imens, we sought to explore the temporal efficiency of our
real-time PCR procedure. We found that approximately
50% (2 hrs.) of the total time required to execute the assay
procedure was spent on the process of extraction of
nucleic acid from clinical specimens. We investigated
whether it would be feasible to detect HSV DNA in crude
(unextracted) clinical specimens using the same Real-
Time PCR reagents and methods currently utilized in our
laboratory. We hypothesized that the diluted nature of the
swab specimens that we regularly analyze, along with the
typical lack of any gross contamination of the viral trans-
port buffers would allow specimens to be analyzed
directly by PCR. Also considered in this hypothesis, was
the fact that the first 10 minutes of our PCR procedure
included a 95°C denaturation step, which might allow for
adequate dissociation of viral nucleic acid from other viral
and host components.
We explored the feasibility of real-time PCR for the detec-
tion of HSV in unextracted clinical specimens by analyz-
ing three specimens which recently had been detected and
typed in our laboratory. The three clinical specimens
included a positive HSV-1, positive HSV-2 and negative
HSV, (as determined by cell culture and IFA). These three
specimens (200 μl each) were subjected to automated
nucleic acid extraction with a 50 μl elution volume per
specimen. Extracted specimens (5 μl) were then analyzed
by HSV 1/2- specific real-time PCR. Simultaneous to this,
samples of those same three clinical specimens were also
analyzed by real-time PCR, using 5, 2.5 and 1 μl of crude,
unextracted specimen combined with water (if necessary)
to achieve a final volume of 5 μl. As shown in Figure 1, the
amplification curves for 5 μl of extracted specimens were
nearly identical to the curves generated when either 1 μl or
2.5 μl of crude specimen was analyzed. This finding was
true for both the HSV-1 and HSV-2 specimens tested (Fig-
ures 1A, 1B). The use of 5 μl of unextracted clinical speci-
men did not appear to significantly alter the crossing
points of either specimen relative to extracted sample.
However, the use of 5 μl of unextracted specimen did have
an impact on some aspect of the amplification or detec-
tion process, as such curves possessed jagged composi-
tions, with much lower maximum fluorescence. Known
negative clinical specimen did not show any amplification
when 5, 2.5 or 1 μl of crude, unextracted specimen were
subjected to PCR relative to the extracted version of the
same specimen (Figure 1C).
Included in all real-time PCR reactions was an internal
control which utilized the same primers, but a different
probe than those used to detect HSV (the probes for these
internal controls emit light at a wavelength of 705 nm)
(Figures 1D, 1E and 1F). The internal control reactions
functioned properly (i.e. they showed exponential ampli-
fication) for all specimens shown in figures 1A, 1B and 1C
when either 1 or 2.5 μl of specimen was analyzed. How-
ever, in each case where 5 μl of crude clinical sample was
analyzed, the internal controls either failed to amplify
efficiently (Figures 1D, 1E), or did not amplify at all (Fig-
ure 1F) indicating that the fundamental chemistry of PCR
was negatively affected by something in the crude speci-
men, but that a significant amount of the crude specimen
was required to be added to the reaction for such a nega-
tive impact to occur. In the cases where HSV-1 and HSV-2
clinical specimens were tested (Figures 1D and 1E),
amplification of the internal control was merely delayed
when 5 μl of clinical specimen was used. Hence, these
specimens would have still been considered as valid spec-
imens for analysis by the testing protocol utilized herein.
However, in the case of the negative clinical specimen in
which 5 μl of raw specimen was tested (Figure 1F), ampli-
fication of the internal control was completely inhibited.
Such a specimen would not have been considered 'nega-
tive' for HSV. Rather, this specimen would have been con-
sidered invalid, and an additional clinical specimen from
the patient would have to have been ordered.
Evaluation of PCR performance with extracted and 
unextracted prospective and retrospective specimens
With preliminary evidence that crude, unextracted clinical
swab specimens, when used in the proper amounts, are
adequate for direct PCR analysis, we sought to determine
the repeatability of this finding. Consecutive prospective
specimens submitted to our laboratory for HSV testing (n
= 36) were subjected to attempted isolation by cell cul-
ture. All cultures with evidence of cytopathic effect were
subsequently tested by immunofluorescence assay (IFA)
for typing. Simultaneous to those tests, specimens were
subjected to HSV-specific real-time PCR in either extracted
(5 μl) or unextracted (1 μl) form. Although both 1 μl and
2.5 μl of crude specimen had performed adequately in
PCR in our initial feasibility study, as shown in Figures 1A
and 1B, we chose to use 1 μl for the remainder of the study
for the reason that such a volume would carry over a
smaller amount of potentially inhibiting factors, if any, in
the clinical specimen. As shown in Table 1 [see Additional
File 1], using a crossing point of 30 as the limit of detec-
tion, the ability to detect HSV DNA(either type 1 or type
2) in clinical specimens was perfectly concordant for
extracted and unextracted specimens. The genetic typing
of positive specimens as either HSV-1 or HSV-2 was also
100% concordant between extracted and unextracted
specimens. One specimen determined to be undetectableBMC Infectious Diseases 2006, 6:104 http://www.biomedcentral.com/1471-2334/6/104
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HSV Clinical Specimens, Analyzed by Real-Time PCR Using Extracted and Unextracted Specimens Figure 1
HSV Clinical Specimens, Analyzed by Real-Time PCR Using Extracted and Unextracted Specimens. Clinical 
specimens found to be positive for HSV-1 (A), HSV-2 (B), or found to be negative for HSV (C) when analyzed by cell culture 
and immunofluorescence microscopy were analyzed by real-time PCR using nucleic acid-extracted and unextracted samples of 
each specimen. The amplification curves for the internal controls of the reactions shown in A, B and C are shown in D, E and 
F respectively. For extracted samples, 200 μl of a clinical specimen (in viral transport buffer) was subjected to automated total 
nucleic acid extraction with an elution volume of 50 μl; 5 μl of the eluted sample was analyzed. For unextracted samples, 5 μl, 
2.5 μl and 1 μl of straight clinical specimen were analyzed. The specimens were taken by swab of genital lesion of a male (A, D) 
or female (B, C, E, F). The swabs were placed in viral transport buffer and stored frozen (-35°C) until analysis. Probes hybridiz-
ing to HSV DNA were detected in the 640 nm channel of a Light Cycler 2.0. Probes specific for internal control DNA were 
detected in the 705 nm channel. The positive real-time PCR control in Figure 1C was 10,000 copies of a purified plasmid con-
taining HSV-2 DNA target fragment (provided by the real-time PCR kit).BMC Infectious Diseases 2006, 6:104 http://www.biomedcentral.com/1471-2334/6/104
Page 5 of 9
(page number not for citation purposes)
by the method of viral culture was found to be positive by
PCR whether the reaction was performed on extracted or
crude samples of that specimen. These findings reinforce
that nucleic extractions are not necessary when analyzing
clinical specimens for the presence of HSV DNA by PCR.
These data also indicate that PCR can still be a more sen-
sitive method than viral culture as a means of HSV detec-
tion, whether or not the tested specimen is subjected to
nucleic acid extraction prior to analysis. All specimens
found to be negative by real-time PCR possessed exponen-
tial amplification curves for internal control PCR (data
not shown).
To determine whether the physiological source of the clin-
ical specimen affects whether extraction is necessary for
PCR analysis, we extended our analysis to include 21 ret-
rospectively evaluated specimens. Specimens were
selected so that a range of samples from various anatomi-
cal sites, from both sexes, would be represented. In addi-
tion, one of the chosen retrospective specimens was
selected because it had previously been found to be nega-
tive by cell culture but positive by PCR (using extraction)
in our laboratory. This specimen was analyzed in order to
determine whether the improved sensitivity demon-
strated by PCR over cell culture using extracted specimens
could be maintained when the PCR was performed using
unextracted specimens.
As shown in Table 2 [see Additional File 2], results for PCR
testing of extracted and unextracted versions of all retro-
spective specimens indicated that both forms of speci-
mens were detectable. One specimen which was
previously determined to be negative by way of cell cul-
ture and positive by real-time PCR was found to be posi-
tive by PCR whether or not the specimen was subjected to
extraction. All specimens found to be negative by real-
time PCR possessed exponential amplification curves for
internal control PCR (data not shown). These data con-
firm that extraction of nucleic acid from clinical HSV spec-
imens is not necessary prior to PCR detection, and that the
enhanced sensitivity of PCR over cell culture for HSV
detection is at least not completely sacrificed when the
extraction step is bypassed. Moreover, these data indicate
that clinical specimens taken from a variety of anatomical
sites may be subjected to PCR without prior nucleic acid
extraction.
Comparison of the sensitivities of PCR using extracted and 
unextracted specimens
On a qualitative basis, the data in Tables 1 and 2 [see
Additional Files 1 and 2] show 100% concordance of PCR
results for extracted and unextracted clinical specimens.
However, inspection of the crossing point values of each
analyzed specimen reveals a trend of disparity between
extracted and un-extracted specimens. For prospectively
analyzed HSV-2 specimens, the average crossing point for
extracted specimens was 14.69, while the average crossing
point for the same specimens analyzed in unextracted
form was 16.26 (a difference of 1.57). Similarly for pro-
spective HSV-1 specimens, the averages for extracted and
unextracted specimens were 15.68 and 17.17 respectively
(a difference of 1.49). These differences indicate that spec-
imens analyzed in the extracted form are more readily
detected than specimens run in unextracted form. Such a
difference would be expected, based on the methodology:
During nucleic acid extraction, 200 μl of clinical specimen
is lysed, purified, and finally eluted in 50 μl of elution
buffer. Hence, assuming that nucleic acid extraction
resulted in 100% recovery of HSV DNA, the eluted speci-
men theoretically contains 4 μl equivalents of original
clinical specimen (200 μl original specimen/50 μl eluted
specimen) per microliter. When 5 μl of extracted, eluted
sample is analyzed by PCR, this correlates to 20 μl equiv-
alent of original clinical specimen. In this study, when the
same clinical specimen was analyzed in unextracted form,
only 1 μl of original clinical specimen was utilized. This
difference in the amount of extracted and unextracted
specimen used in PCR implied that the theoretical sensi-
tivity enhancement of HSV PCR using extracted versus
unextracted specimens should be at least 20-fold. Others
have found however, that the process of automated
nucleic acid extraction we utilized herein results in far less
than 100% recovery of nucleic acid from specimens [5].
Hence, we sought to determine the yield of nucleic acid
extraction by this automated method in our lab. To do
this, we utilized quantified plasmids containing HSV
DNA target fragments (provided by the real-time PCR kit),
combined with known negative clinical HSV specimens.
Such spiked formulations containing known amounts of
HSV DNA target fragment were then subjected to nucleic
acid extraction, and the eluted samples were quantified by
real-time PCR. HSV-2 DNA target fragments (90,000 cop-
ies in 200 μl of non-HSV-containing (negative) clinical
specimen) were subjected to automated extraction, and
were eluted to a final volume of 50 μl. Subsequent quan-
titative PCR analysis showed that the average yield (recov-
ery) of three extractions was 24.1%. Using this factor, a
comparison of sensitivities of the use of extracted and
unextracted specimens in PCR was reconsidered: In the
context of this work, using 5 μl of extracted specimen was
actually the equivalent of analyzing only 4.8 μl of original
specimen. Hence, the sensitivity of PCR for HSV detection
using extracted specimens is approximately only 5 fold
greater than the sensitivity of the same PCR using unex-
tracted specimen. In accordance with this, we have rou-
tinely found with the RealArt HSV 1/2 LC PCR Kit that a
3-cycle crossing point differential correlates to an approx-
imate 10-fold difference in target DNA concentration.
This in agreement with the finding that extracted speci-BMC Infectious Diseases 2006, 6:104 http://www.biomedcentral.com/1471-2334/6/104
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mens possess crossing points approximately 1.5 cycles
lesser than those of their unextracted counterparts.
To further evaluate the sensitivity of PCR on unextracted
clinical specimens, we performed real-time PCR analysis
on dilutions of previously quantified stocks of patient-
derived HSV particles. HSV-1 and HSV-2 stocks contain-
ing 3.4 × 107 and 1.02 × 108 virus particles per millilitre
respectively were subject to 2-fold serial dilution using a
HSV-negative clinical specimen as a diluent. Dilutions
were subject to real-time PCR in the unextracted form to
determine the maximum dilution of whole, unextracted
virus particles detectable by the assay. For HSV-1, a diluted
sample theoretically containing 17 virus particles (1 μl of
a 1/2000 dilution) was the maximum detectable dilution,
giving a crossing point value of 27.98. For HSV-2, a
diluted sample theoretically containing 32 virus particles
per microliter (1 μl of a 1/3200) was the maximum detect-
able dilution, giving a crossing point value of 26.59. Puri-
fied HSV-1 and HSV-2 target DNA standard (provided by
the kit) were found to be detectable at a minimum level of
10 copies in 4 out of 4 reactions, with the highest detected
crossing point values being 26.77 for HSV-2 and 25.53 for
HSV-1. These data confirm that there is a sensitivity loss
for real-time PCR when HSV is detected in the unextracted
form compared to the detection of purified DNA.
Table 1: Prospective Clinical HSV Specimens
Specimen Culture/IFA Real-Time PCR
Extracteda Unextractedb
Gender Site Culture IFA Result CP value Type Result CP value Type
F genital positive HSV-2 positive 9.87 HSV-2 positive 12.49 HSV-2
M genital positive HSV-2 positive 10.95 HSV-2 positive 12.16 HSV-2
M genital positive HSV-1 positive 11.03 HSV-1 positive 12.18 HSV-1
F genital positive HSV-2 positive 11.82 HSV-2 positive 12.70 HSV-2
F genital positive HSV-2 positive 13.10 HSV-2 positive 15.28 HSV-2
M genital positive HSV-2 positive 13.35 HSV-2 positive 15.69 HSV-2
F genital positive HSV-2 positive 13.80 HSV-2 positive 16.83 HSV-2
F genital positive HSV-2 positive 13.97 HSV-2 positive 15.20 HSV-2
M genital positive HSV-1 positive 15.27 HSV-1 positive 16.09 HSV-1
M genital negativec n/a positive 16.06 HSV-1 positive 18.18 HSV-1
F genital positive HSV-2 positive 16.97 HSV-2 positive 17.22 HSV-2
M genital positive HSV-2 positive 17.47 HSV-2 positive 18.85 HSV-2
F genital positive HSV-2 positive 17.60 HSV-2 positive 18.49 HSV-2
M rectal positive HSV-2 positive 19.48 HSV-2 positive 21.82 HSV-2
M genital positive HSV-1 positive 20.37 HSV-1 positive 22.29 HSV-1
M genital positive HSV-2 positive 20.66 HSV-2 positive 22.60 HSV-2
F genital positive HSV-2 positive 22.64 HSV-2 positive 23.92 HSV-2
F genital negative n/a negative negative negative negative
M rectal negative n/a negative negative negative negative
M rectal negative n/a negative negative negative negative
F rectal negative n/a negative negative negative negative
M rash/lesion negative n/a negative negative negative negative
M genital negative n/a negative negative negative negative
F genital negative n/a negative negative negative negative
M rectal negative n/a negative negative negative negative
M genital negative n/a negative negative negative negative
M genital negative n/a negative negative negative negative
F genital negative n/a negative negative negative negative
M rectal negative n/a negative negative negative negative
M genital negative n/a negative negative negative negative
M genital negative n/a negative negative negative negative
M rash/lesion negative n/a negative negative negative negative
M rectal negative n/a negative negative negative negative
a 5 ul of extracted nucleic acid used in PCR
b 1 ul of straight clinical specimen used in PCR
c specimen was negative for HSV by cell culture; positive by real-time PCR
n/a specimen was not analyzed
CP value Crossing Point of real-time PCRBMC Infectious Diseases 2006, 6:104 http://www.biomedcentral.com/1471-2334/6/104
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Discussion
The data described in this work indicate that real-time
PCR for the detection of herpes simplex viruses can be per-
formed without previous extraction and purification of
nucleic acid from clinical samples. It is important to
emphasize that this assertion is made only in the context
of specimens collected by swabs which have been put into
contact with anatomical sites and subsequently diluted
into a commonly utilized viral transport buffer. Speci-
mens collected in this way probably contain very little
physiological debris, and what little debris that is carried
by the swab is diluted greatly into transport buffer. Also,
the first step of this (and many) PCR protocol involves 10
minutes at 95°C. At this temperature, many bio-mole-
cules will be denatured and solubilised, allowing for lip-
ids and protein complexes to disassociate, hence allowing
for exposure of target nucleic acids to the detection chem-
istry reactants (e.g. primers, probes, enzymes). Moreover
PCR protocols call for a relatively small amount of such
diluted specimen be placed within the PCR reaction, fur-
ther diluting-out any potential inhibitors. Whether or not
PCR can be carried out on non-extracted, non-purified
specimens is certainly a matter to be determined empiri-
cally, on a case-by-case basis. However the data provided
herein imply that it may very well be worth considering
omission of nucleic acid extraction steps in cases where
dilution of potential inhibitors takes place during speci-
men collection or in cases where the clinically collected
specimen is thought to be relatively free of potential
inhibitors. Certain conditions demand that nucleic acid
extraction and purification be performed prior to PCR.
This is true for protocols involving RNA viruses, where
reverse transcription of RNA into DNA must take place
prior to PCR. Since such protocols involve reverse tran-
scription steps that take place at relatively lower tempera-
tures (often 48°C) before the denaturation step (95°C or
greater), access of enzymes to viral RNA is required.
Attempts to perform reverse-transcription-PCR on speci-
mens known to contain influenza A virus (an RNA virus)
in our laboratory were not successful without first extract-
ing and purifying nucleic acid.
Our use of PCR to detect HSV in specimens in lieu of
nucleic acid extraction was not without some sacrifice in
the sensitivity of the assay. Using 1 μl of raw clinical spec-
imen resulted in an approximate 2 to 5-fold reduction in
Table 2: Retrospective Clinical HSV specimens
Specimen Culture/IFA Real-Time PCR
Extracteda Unextractedb
Gender Site Culture IFA Result CP value Type Result CP value Type
M rectal positive HSV-1 positive 7.09 HSV-1 positive 10.44 HSV-1
F genital positive HSV-1 positive 8.49 HSV-1 positive 11.01 HSV-1
F genital positive HSV-2 positive 12.55 HSV-2 positive 15.28 HSV-2
F genital positive HSV-2 positive 13.14 HSV-2 positive 15.32 HSV-2
M genital positive HSV-1 positive 13.14 HSV-1 positive 14.98 HSV-1
M genital positive HSV-1 positive 13.23 HSV-1 positive 15.68 HSV-1
M rectal positive HSV-1 positive 13.27 HSV-1 positive 14.51 HSV-1
M genital positive HSV-2 positive 13.70 HSV-2 positive 15.98 HSV-2
M rash/lesion positive HSV-1 positive 13.73 HSV-1 positive 15.82 HSV-1
F genital positive HSV-1 positive 14.54 HSV-1 positive 15.53 HSV-1
F rash/lesion positive HSV-2 positive 14.87 HSV-2 positive 17.99 HSV-2
M rectal positive HSV-2 positive 15.84 HSV-2 positive 20.13 HSV-2
F genital negativec n/a positive 17.91 HSV-2 positive 19.88 HSV-2
M rash/lesion positive HSV-2 positive 18.35 HSV-2 positive 21.31 HSV-2
M rectal positive HSV-2 positive 19.96 HSV-2 positive 21.58 HSV-2
F rash/lesion positive HSV-1 positive 20.73 HSV-1 positive 22.36 HSV-1
M genital positive HSV-2 positive 23.56 HSV-2 positive 24.98 HSV-2
M genital negative n/a negative negative negative negative
M rash/lesion negative n/a negative negative negative negative
F genital negative n/a negative negative negative negative
M rectal negative n/a negative negative negative negative
a 5 ul of extracted nucleic acid used in PCR
b 1 ul of straight clinical specimen used in PCR
c specimen was negative for HSV by cell culture; positive by real-time PCR
n/a specimen was not analyzed
CP value Crossing Point of real-time PCRBMC Infectious Diseases 2006, 6:104 http://www.biomedcentral.com/1471-2334/6/104
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sensitivity relative to when extracted specimens were used.
However, this level of sensitivity loss does not seem con-
siderable in terms of detecting infection in patients. It is
typical for skin lesions caused by HSV to secrete very high
concentrations of virus particles [1]. This is corroborated
by the study herein involving both prospective and retro-
spective clinical specimens. In all of the positive clinical
specimens detected, the highest crossing point value iden-
tified by PCR of unextracted specimens was 24.98, with
the vast majority of positive specimens possessing cross-
ing point values less than 22, which correlates to approx-
imately 500 virus particles per microliter in our assay
(data not shown). Hence, it appears that the consequen-
tial loss of sensitivity of approximately 1.5 crossing point
values for analysis of unextracted specimens will very
rarely render a positive specimen undetectable by the
unextracted real-time PCR method. In this body of data,
we identified two low-positive specimens (culture-nega-
tive, PCR-positive using extracted specimen samples) that
were readily detected by real-time PCR when raw, unex-
tracted specimen samples were analyzed. It should also be
noted that in this study, we chose to analyze only 1 μl of
clinical specimen. This amount was chosen in the interest
of generating a conservative estimate of the capabilities of
unextracted PCR for HSV, while additionally maintaining
a low probability of carrying over a physiologic inhibitor
to PCR. Our results showed that as much as 2.5 μl could
be analyzed per reaction. If such an amount was used,
then the sensitivity difference between PCR on extracted
and unextracted specimens might be less than 2-fold.
Moreover, the data herein indicate that the use of a cross-
ing point value of 30 as a cut-off for detection of impure
specimens may have been unnecessarily high. Noting that
the highest crossing point generated for an unextracted
specimen was 27.98 for the smallest detected amount of
whole virus (17 HSV-1 particles), we intend to consider
28 as a crossing point maximum for assigning positive sta-
tus to a specimen.
The use of PCR without extensive nucleic acid extraction
of specimens is not without precedent. Polymerase chain
reaction for the detection of Bordetella pertussis has been
reliably achieved using swabs merely agitated in water and
heated for ten minutes [6]. Real-time PCR for the detec-
tion and quantification of adeno-associated viral vectors
was shown to work very well on a routine basis, with a
two-fold approximate loss in sensitivity in the ability to
detect unextracted AAV particles relative to those sub-
jected to nucleic acid extraction [7].
Other simplifications of the overall process of using PCR
to diagnose HSV infections have been shown to be effec-
tive. Filen et al have shown that dry cotton swabs in an
empty transport tube are just as effective as those placed
in viral transport buffer when used subsequently in real-
time PCR [1]. Such findings, combined with those in this
work, may operate well together towards establishment of
a greatly simplified diagnostic protocol. Simplification of
the overall protocol might greatly eliminate the possibility
of contamination during sample processing, while short-
ening assay time.
Real-time, quantitative PCR is becoming commonplace in
both the clinical and public health laboratory settings.
The cost of consumables, reagents and labor that is
required to operate a PCR-capable laboratory can be pro-
hibitive. Hence, studies that critically evaluate the rele-
vancy of the individual steps of complex protocols such as
PCR may result in modifications to protocols which save
time and money, with a minimal sacrifice in assay per-
formance.
Conclusion
Clinical specimens consisting of swabbed lesions thought
to be caused by herpes simplex virus (HSV, type 1 or 2)
can be analyzed by real-time PCR in lieu of nucleic acid
extraction and purification. Analysis of specimens by real-
time PCR without previous extraction/purification of
nucleic acid results in an approximate 2 to 5-fold loss in
sensitivity, with no discernable loss of specificity. The sen-
sitivity loss which occurs when specimens are analyzed in
this way still results in a highly sensitive assay relative to
cell culture based isolation. Moreover, the exclusion of
nucleic acid extraction results in a considerable savings in
both time and money.
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